Aspergillosis Treatment Market To Reach $5.79 Billion By 2030

Aspergillosis Treatment Market Growth & Trends

The global aspergillosis treatment market size is expected to reach USD 5.79 billion by 2030, registering a CAGR of 3.99% from 2023 to 2030, according to a new report by Grand View Research, Inc. The rising incidence of aspergillosis infections, particularly among immunocompromised individuals, has spurred the demand for innovative treatment approaches. Rapid advancements in medical technology and drug development have led to the introduction of more targeted and effective therapies, enhancing patient outcomes and treatment efficacy. Improved awareness and diagnostic capabilities contribute to early detection and prompt treatment initiation, further increasing the demand for various drugs. The existing treatment paradigm predominantly relies on the utilization of conventional antifungal drugs such as azoles (such as Itraconazole and voriconazole), in addition to antibiotics and corticosteroids.

Several prominent companies such as F2G, TFF Pharmaceuticals, Scynexis, and Pulmocide are in the process of introducing innovative therapeutic strategies that hold the potential to reshape the landscape of Invasive Aspergillosis treatment. The successful launch of such candidates could pose a substantial challenge to the established pharmaceutical leaders in the market. This challenge would arise from their capacity to revolutionize the established standard of care, thereby offering a transformative approach for patients.

Companies and researchers are currently engaged in evaluating challenges and identifying potential opportunities that could impact the research and development (R&D) and treatment landscape. The ongoing efforts in this field are centered around innovative strategies aimed at addressing and enhancing the management of Aspergillosis. For instance, in April 2022, Pulmatrix announced the restoration of complete rights to its portfolio of narrow-spectrum kinase inhibitors (NSKIs), which includes PUR1800.

This decision came about after the determination by Johnson & Johnson's Enterprise Innovation to terminate the licensing, development, and commercialization agreement previously established with Pulmatrix. In response, Pulmatrix has outlined its intention to proceed with the advancement of PUR1800. The company plans to continue the progression of this compound by conducting continuous clinical assessments and toxicology studies. These endeavors are undertaken to bolster programs focused on acute exacerbations in Chronic Obstructive Pulmonary Disease (COPD) as well as other chronic respiratory conditions.

 Request a free sample copy or view report summary: Aspergillosis Treatment Market Report

Aspergillosis Treatment Market Report Highlights

• Based on type, the allergic segment held the largest revenue share in 2022, the growth can be attributed to higher prevalence and milder disease presentation, particularly in conditions such as allergic bronchopulmonary aspergillosis (ABPA) affecting asthma and cystic fibrosis patients

• Based on drug class, the antifungal drug segment held the largest revenue share in 2022, the growth can be attributed to their effectiveness in combating aspergillosis infections and their wide usage as a primary treatment option

• Based on route of administration, the oral drugs segment held the largest revenue share in 2022. This growth is due to its convenience and patient-friendly administration, making it a preferred choice for both healthcare providers and patients

• Based on distribution channel, the hospital pharmacy segment dominated the market with a share of 47.59% in 2022. This growth is due to the pivotal role that hospital-based distribution channels play in the effective delivery and accessibility of treatments for aspergillosis

• North America dominated the market in 2022. This dominance can be attributed to a confluence of factors that underscore the region's advanced healthcare infrastructure, dynamic research and development (R&D) endeavors, access to cutting-edge medical technologies

Aspergillosis Treatment Market Segmentation

Grand View Research has segmented the global aspergillosis treatment market based on type, drug class, route of administration, distribution channel, and region:

Aspergillosis Treatment Type Outlook (Revenue in USD Million, 2018 - 2030)

• Allergic Aspergillosis

• Chronic Aspergillosis

• Invasive Aspergillosis

Aspergillosis Treatment Drug Class Outlook (Revenue in USD Million, 2018 - 2030)

• Antifungal drugs

  • Azoles

  • Echinocandins

  • Polyenes

  • Allylamines

  • Others

• Others

Aspergillosis Treatment Route Of Administration Outlook (Revenue in USD Million, 2018 - 2030)

• Oral Drugs

• Ointments

• Powders

• Others

Aspergillosis Treatment Distribution Channel Outlook (Revenue in USD Million, 2018 - 2030)

• Hospital Pharmacy

• Retail Pharmacy

• Others

Aspergillosis Treatment Regional Outlook (Revenue in USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Norway

  • Denmark

• Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa

  • Saudi Arabia

  • South Africa

  • UAE

  • Kuwait

List of Key Players in the Aspergillosis Treatment Market

• Pfizer, Inc.

• Merck & Co.

• F2G

• Novartis AG

• Astellas Pharma Inc.

• Bayer AG

• Mayne Pharma Group Limited

• PULMATRiX, Inc.